References
1. Behera SK, Das S, Xavier AS, Velupula S, Sandhiya S. Comparison of different methods for causality assessment of adverse drug reactions. Int J Clin Pharm 2018; 40: 903-10.
2. Thaker SJ, Sinha RS, Gogtay NJ, Thatte UM. Evaluation of inter-rater agreement between three causality assessment methods used in pharmacovigilance. J Pharmacol Pharmacother 2016; 7: 31-3.
3. Varallo FR, Planeta CS, Herdeiro MT, Mastroianni PC. Imputation of adverse drug reactions: Causality assessment in hospitals. PLoS One 2017; 12: e0171470.
4. Khan LM, Al-Harthi SE, Osman AM, Sattar MA, Ali AS. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm J 2016; 24: 485-93.
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
6. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27: 538.
7. Shajahan J, Aslam Parathoduvil A, Purushothaman S. An analysis of seriousness, predictability and preventability of adverse drug reactions reported at a tertiary care teaching hospital in Kerala, India: a retrospective observational record based study. International Journal of Basic & Clinical Pharmacology 2018; 7: 2433-38.
8. WHO. The Conceptual Framework for the International Classification for Patient Safety. In: World Health Organization, 2009.
9. Silva MDDG, Martins MAP, Viana LG, Passaglia LG, de Menezes RR, Oliveira JAQ, da Silva JLP, Ribeiro ALP. Evaluation of accuracy of IHI Trigger Tool in identifying adverse drug events: a prospective observational study. Br J Clin Pharmacol 2018; 84: 2252-59.
10. Fleiss JL. Measuring nominal scale agreement among many raters. Psychological Bulletin 1971; 76: 378-82.
11. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968; 70: 213-20.
12. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
13. Mouton JP, Mehta U, Rossiter DP, Maartens G, Cohen K. Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system. PLoS One 2017; 12: e0172830.
14. Center UM. The use of the WHO-UMC systemfor standardised case causality assessment. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Acessed Jun 10, 2019
15. Hakkarainen KM, Hedna K, Petzold M, Hagg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions–a meta-analysis. PLoS One 2012; 7: e33236.